Citadel Advisors
ABCL icon

Citadel Advisors’s AbCellera Biologics ABCL Stock Holding History

Citadel Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$304K Sell
87,200
-87,900
-50% -$316K ﹤0.01% 10440
2025
Q4 		$599K Sell
175,100
-61,300
-26% -$274K ﹤0.01% 8599
2025
Q3 		$1.19M Sell
236,400
-6,600
-3% -$29.1K ﹤0.01% 7161
2025
Q2 		$833K Buy
243,000
+73,800
+44% +$184K ﹤0.01% 7490
2025
Q1 		$377K Sell
169,200
-3,000
-2% -$8.6K ﹤0.01% 9087
2024
Q4 		$505K Buy
172,200
+73,900
+75% +$206K ﹤0.01% 8533
2024
Q3 		$256K Buy
98,300
+32,700
+50% +$90.6K ﹤0.01% 9630
2024
Q2 		$194K Sell
65,600
-11,300
-15% -$42.8K ﹤0.01% 9986
2024
Q1 		$348K Sell
76,900
-53,700
-41% -$274K ﹤0.01% 9158
2023
Q4 		$746K Buy
130,600
+50,000
+62% +$232K ﹤0.01% 7257
2023
Q3 		$371K Buy
80,600
+5,500
+7% +$33.5K ﹤0.01% 8710
2023
Q2 		$485K Buy
75,100
+3,800
+5% +$25.9K ﹤0.01% 8007
2023
Q1 		$538K Sell
71,300
-127,200
-64% -$1.16M ﹤0.01% 8154
2022
Q4 		$2.01M Sell
198,500
-20,500
-9% -$237K ﹤0.01% 5478
2022
Q3 		$2.17M Sell
219,000
-74,400
-25% -$816K ﹤0.01% 5434
2022
Q2 		$3.13M Buy
293,400
+200,800
+217% +$1.7M ﹤0.01% 4688
2022
Q1 		$903K Buy
92,600
+17,400
+23% +$165K ﹤0.01% 7944
2021
Q4 		$1.07M Sell
75,200
-43,300
-37% -$657K ﹤0.01% 7771
2021
Q3 		$2.38M Sell
118,500
-77,800
-40% -$1.38M ﹤0.01% 5925
2021
Q2 		$4.32M Buy
196,300
+180,200
+1,119% +$4.97M ﹤0.01% 4757
2021
Q1 		$547K Buy
+16,100
New +$641K ﹤0.01% 9477

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ABCL Position: Q1 2026 in Review

Citadel Advisors reduced its AbCellera Biologics (ABCL) stake by 26% in Q1 2026, selling an estimated $1.7M and leaving 1,361,105 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

Citadel Advisors first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $17.4M in Q4 2020. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Citadel Advisors held 1,361,105 shares of AbCellera Biologics worth $4.75M as of Q1 2026.
  • Citadel Advisors sold 473,403 AbCellera Biologics shares in Q1 2026, an estimated $1.7M.
  • AbCellera Biologics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4428 holding.
  • Citadel Advisors first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's AbCellera Biologics position peaked at $17.4M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.